RadarScope: JNJ — Analiza Fundamentala

Market Cap

$634.8B

P/E Ratio

30.4

Profit Margin

21.5%

ROE

25.7%

📈 Earnings Report — 2026-07

Ultimul trimestru raportat

EPS Actual

$2.9

▲ 7.4% QoQ▲ 4.7% YoY

EPS Estimat

$2.84

Beat by 2.1%

Revenue Actual

$25.31B

▲ 5.2% QoQ▲ 6.6% YoY

Revenue Estimat

$25.06B

Beat by 1.0%

Istoric Ultimele 4 Trimestre

2026-07

EPS Actual

$2.9

EPS Est.

$2.84

Revenue

$25.31B

Beat/Miss

Beat by 2.1%

2026-04

EPS Actual

$2.7

EPS Est.

$2.68

Revenue

$24.06B

Beat/Miss

Beat by 0.7%

2026-01

EPS Actual

$2.46

EPS Est.

$2.46

Revenue

$24.56B

Beat/Miss

Beat by 0.0%

2025-10

EPS Actual

$2.8

EPS Est.

$2.76

Revenue

$23.99B

Beat/Miss

Beat by 1.4%

Urmatorul Raport

Data

2026-10-13

EPS Estimat

$2.95

Revenue Estimat

$25.32B

💰 Dividende Recente

2026-08

$1.34

Yield: 2.01%

Plata: 2026-09

2026-05

$1.34

Yield: 2.28%

Plata: 2026-06

2026-02

$1.3

Yield: 2.11%

Plata: 2026-03

2025-11

$1.3

Yield: 2.49%

Plata: 2025-12

📊 Scoruri Companie

Crestere 7/10

Revenue & Profit Growth

Evaluare 5/10

P/E · P/B · P/S

Calitate 10/10

Marje · ROE · Datorii

Risc 3/10

Beta · Market Cap

📈 Date Financiare Istorice in miliarde USD

💰 Revenue

📊 Net Profit

💵 Cash Flow

Operating (albastru) · Free (violet)

🏦 Cash & Datorii

Cash (verde) · Long-term Debt (rosu)

💸 Operating Expenses

🤖 Analiza RadarScope AI

Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.

💡 Disponibil pe Trader / Elite

🐂 BULL CASE

Disponibil pe Trader / Elite

🐻 BEAR CASE

Disponibil pe Trader / Elite

TINE Upgrade la Trader sau Elite pentru verdictul AI.

📖 Indicatorii lui Lynch — concluzii rapide dupa Peter Lynch

PEG — P/E in contextul cresterii

SCUMP

PEG 2.04 · cu dividend 1.8 · crestere EPS ~14.9%/an. Regula Lynch: ~1 corect, sub 0.5 foarte atractiv, peste 2 scump.

P/E vs istoria proprie si sectorul

P/E acum 30.4.
vs media proprie 5 ani (20.4): PESTE media sa
vs sector Healthcare (22.8): PESTE sector
Lynch: compara P/E cu propria istorie si media industriei, nu in absolut.

Procentul din vanzari (concentrare produs)

CONCENTRAT PE 1 PRODUS

Innovative Medicine 64% · MedTech 36%
Lynch: un produs genial care aduce sub ~10% din venituri nu misca actiunea.

Cash si datorie

DATORIE NETA

Datorie neta pe actiune $11.55 (mai multa datorie decat cash).
Datorie/Capital 0.58 DATORIE MODERATA — decide supravietuirea in vremuri grele (esential la ciclice si turnarounds).
Tip datorie: OK — TERMEN LUNG — majoritar pe termen lung (obligatiuni = timp de manevra). Scurt $8.5B / Lung $39.4B.

Marje de profit

MARJE SOLIDE

Bruta 70.5% · Operationala 26.8% · Neta 21.5%. Marje mari — de regula castigatorul pe termen lung din industrie.

Inventare vs vanzari

ATENTIE

Stocurile cresc mai repede ca vanzarile (inventar +14% vs vanzari +6%) — semnal de alarma clasic.

Povestea in 2 minute

De ce o detii: Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.
Ce trebuie sa mearga bine: Disponibil pe Trader / Elite
Obstacole: Disponibil pe Trader / Elite
Lynch: daca nu poti explica coerent in 2 minute de ce o detii, nu o intelegi.

🔬 Analiza Fundamentala Avansata · an fiscal 2025-12-31

🏦 Altman Z-Score

4.27 ZONA SIGURA

X1 Capital de lucru / Active	0.008	x1.2
X2 Profit reportat / Active	0.0	x1.4
X3 EBIT / Active	0.168	x3.3
X4 Capitalizare / Datorii	5.395	x0.6
X5 Vanzari / Active	0.473	x1.0

Praguri Altman (1968): >2,99 sigur · 1,81–2,99 gri · <1,81 pericol de faliment

💪 Piotroski F-Score

4/9 SLAB

✓ROA pozitiv13.46%

✓Cash flow operational pozitiv24.53B

✓ROA in crestere13.46% vs 7.81%

✗Cash flow > Profit net (calitate)24.53B vs 26.80B

✗Datorie pe termen lung in scadere19.8% vs 17.0% din active

✗Lichiditate curenta in crestere1.03 vs 1.11

✓Fara emisiune de actiuni noi2407.9M vs 2406.9M

✗Marja bruta in crestere67.9% vs 69.1%

✗Rotatia activelor in crestere0.47 vs 0.49

9 teste binare (Piotroski, 2000). 8–9 = putere financiara · 0–2 = slabiciune

⚖️ ROIC vs WACC

+19.94pp CREEAZA VALOARE

ROIC (randamentul capitalului)	25.15%
WACC (costul capitalului)	5.20%

Ipoteze (la vedere):
Rata fara risc 4.2% (USD) · Beta 0.23 · Prima de risc 5.5%
Cost capitaluri proprii 5.47% · Cost datorie 2.03% · Impozit efectiv 17.7%

Metode publice: Altman, E. (1968), Journal of Finance · Piotroski, J. (2000), Journal of Accounting Research · ROIC/WACC prin CAPM. Fiecare cifra isi arata componentele si pragurile — poti reface calculul manual.

📊 Metrici Fundamentale

P/E TTM30.4

P/B TTM7.56

P/S TTM6.48

EV/EBITDA19.7

Gross Margin70.5%

Operating Margin26.8%

Net Margin21.5%

ROE25.7%

ROA10.5%

Debt/Equity0.58

Current Ratio1.09

FCF Yield2.9%

Dividend Yield1.99%

Beta0.23

💰 Venituri & Profit (ultimele trimestre)

Trimestru	Revenue	Gross Profit	Net Income	EPS
2026-06	$25.3B	$18.5B	$5.5B	$2.27
2026-03	$24.1B	$17.2B	$5.2B	$2.14
2025-12	$24.6B	$16.6B	$5.1B	$2.10
2025-09	$24.0B	$16.7B	$5.2B	$2.14

🏢 Profil Companie

CEOJoaquin Duato

Angajati141700

IPO1962-01-02

Websitehttps://www.jnj.com...

52W High$274.90

52W Low$173.33

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories....

🎯 Score Breakdown

Calitate Companie (Q) 10/10

Risc Speculativ (R) 3/10

Scor AI RadarScope 0/100

VERDICT FINAL

TINE

Upgrade la Trader sau Elite pentru verdictul AI.

🔒 Analiza completa disponibila cu cont SignalRadar